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Induction of transplantation tolerance remains the ideal
long-term clinical and logistic solution to the current
challenges facing the management of renal allograft
recipients. In this review, we describe the recent studies and
advances made in identifying biomarkers of renal transplant
tolerance, from study inceptions, to the lessons learned and
their implications for current and future studies with the
same goal. With the age of biomarker discovery entering a
new dimension of high-throughput technologies, here we
also review the current approaches, developments, and
pitfalls faced in the subsequent statistical analysis required to
identify valid biomarker candidates.
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Solid organ transplantation is the preferred treatment for end-
stage kidney failure, as it substantially improves patient
survival and quality of life over continued dialysis therapy.
However, in order to avoid rejection, graft recipients have to
undergo lifelong immunosupression (IS). This poses a
difficult challenge for patients and clinicians as a delicate
equilibrium needs to be reached. On one hand, the transplant
needs to be protected with sufficient IS, whereas on the other
hand the patient needs to maintain an immune system that is
healthy enough to fight-off infections and cancer. Moreover,
immunosupressive agents have metabolic side effects (hyper-
tension, hyperlipidemia, and hyperglycemia) that contribute
to the high level of morbidity in patients post-transplantation.
As a consequence, the 10-year overall survival rate of a
transplanted kidney is just above 50% in Europe,1 which puts
a yearly increased strain on the number of people waiting for
further transplants. Causes of transplant failure are diverse,
uncontrolled activity of the inflammatory, and immune
systems being one of the main contributors.2–4
Ideally, the best clinical situation for a transplant recipient
would be the development of donor-specific immunological
tolerance. This would allow long-term patient and graft
survival without the need for IS. Thus, there is a pressing need
to establish the correct level of IS in each patient, such as to
individualize their therapy. In this process, the lack of analytical
parameters able to indicate the correct treatment for each
patient has prompted a wide search for biomarkers of clinical
use in transplantation. In the early-phase post-transplantation,
the ability to predict acute rejection would allow us to adjust IS
accordingly, whereas in the late-phase post-transplantation, our
inability to detect whether a patient has developed a degree of
tolerance to their graft is absolute. This has led us to use the
term ‘the hidden phenotype’. Currently, there are no clinically
validated tools to dictate whether to increase or decrease the
level of IS that each patient needs to be maintained with. In this
review, we will discuss the progress made to date and the future
avenues in the development of biomarkers of immunological
tolerance in kidney transplantation.
THE PAST: THE INDICES OF TOLERANCE STUDY
Despite promising studies reporting the induction of
tolerance in experimental models of solid organ transplanta-
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tion, few of these approaches have been translated to clinical
transplantation. The Indices of Tolerance (IoT) study was
initiated as a necessary shift in the paradigm to approaches of
inducing transplant tolerance. If we could identify the
specific immunological characteristics of tolerance in human
subjects, then we could use more targeted and informed
approaches to tolerance-induction therapies, with the
potential to manipulate the immune compartments respon-
sible for generating donor-specific immune regulation. In
2010, we reported on the findings of the IoT multicenter
study, which was conducted over a period of 6 years, and
culminated in the description of several immunological
characteristics uniquely associated with the tolerant state in
renal transplant patients.5 As an investigator-led study, based
within an academic institute, we were faced with the logistic
challenges of conducting a clinical study from a primarily
bench-based laboratory perspective. Overcoming this was a
steep learning curve for the scientists and clinicians involved
alike. In fact, the first challenge we faced on initiating the
study was the recruitment of tolerant renal transplant
subjects. As described later, the risk of renal allograft loss
due to IS cessation, based on clinical experience, is thought to
be high, and as a consequence, operational tolerance is
estimated to be a rare event. Nevertheless, we were able to
locate 11 tolerant renal transplant recipients throughout
Europe. A number of pathways had led to this outcome, from
medical non-compliance to withdrawal due to malignancies.
We also encountered some exceptional cases, such as a renal
allograft recipient who was unable to gain access to his IS for
several weeks, because of severe flooding, which left him
stranded on his roof. This latter example seems serendipi-
tous, but may also defy the traditional dogma that the
establishment of renal transplant tolerance is a rare
occurrence and needs to occur over a period of time. As
discussed later, currently, this cannot be tested by any
ethically sound approach. By comparing parameters of the
immune system in the identified operationally tolerant
recipients (stable renal transplant recipients who have ceased
all immunosuppressive drugs for more than a year) with
control groups (patients with stable renal function main-
tained on immunosuppressive drugs, patients with biopsy-
proven chronic rejection, and healthy individuals), we
identified a biomarker signature of tolerance. As indicated
later, we adopted both cellular and molecular analytical
approaches in our attempt to identify tolerant patients. One
of the hypotheses tested was to find an absent functional or
active anti-donor immune response. Analysis of cellular
immune components revealed elevated numbers of B and NK
cells in peripheral blood, diminished numbers of recently
activated CD4þ T cells, and donor-specific hyporesponsive-
ness of CD4þ T cells. Further, we identified a discrete set of
genes with altered expression, and a high ratio of FoxP3/a-
1.2-mannosidase gene expression in peripheral blood.
These findings were then validated on an independent
cohort of tolerant renal transplant patients as part of a
collaboration with the Immune Tolerance Network (ITN) in
the USA, which subsequently led to a parallel publication
showing highly comparable findings.6 The cross-platform
approach we adopted toward biomarker identification high-
lighted a particularly prominent role for B cells within
transplantation tolerance, which have very recently re-
emerged with newly defined roles within inflammation and
immunity.7–9
THE PRESENT: THE VALIDATION OF THE BIOMARKERS
OF TOLERANCE
Although a set of biomarkers associated with tolerance had
been defined at the completion of the IoT project, more
questions were then raised: First, would newly identified
tolerant patients show the same biomarkers? Second, would
the biomarker fingerprint of tolerance also be detectable
within groups of renal transplant patients displaying stable
allograft function while undertaking immunosuppressive
regimens? If so, could the fingerprint be used to predict
which patients are more likely to develop tolerance and, as a
consequence, would it be possible to successfully minimize
their IS under supervision? Finally, could the fingerprint also
define patients at the other spectrum of tolerance; that is,
patients undergoing chronic rejection? In which case, a set of
biomarkers could potentially be used as a monitoring tool for
kidney function. To address these questions we initiated our
current project: Genetic Analysis and Monitoring of Bio-
markers of Immunological Tolerance.10
We approached this project with the advantage of having
learned many lessons from the IoT. We have put into place a
network of several participating centers within the United
Kingdom and Europe, together with a continuing firm
collaboration with the ITN. We have recruited a technically
skilled team that includes not only scientists and clinicians
but also statisticians, data managers, and project adminis-
trators. We also now have the benefit of new developments in
high-throughput techniques, which, because of the NIHR
and the UK government investments in translational medical
research, have allowed us to establish the infrastructure,
facilities, and capacity to perform cutting-edge research. In
addition, we are also participants of the International Solid
Organ Transplant Registry, a renal transplant registry aiming
to establish a multicenter database registering patients who
underwent solid organ transplantation, in whom operational
tolerance has developed.11 International Solid Organ Trans-
plant Registry represents a meeting place for patients,
families, and physicians, thus facilitating the enrolment of
interested patients into appropriate studies of transplant
tolerance.
GENETIC ANALYSIS AND MONITORING OF BIOMARKERS
OF IMMUNOLOGICAL TOLERANCE
The aim of the Genetic Analysis And Monitoring Of
Biomarkers Of Immunological Tolerance study is essentially
to assess the biomarkers of tolerance in a larger cohort of
kidney transplant patients. This primary aim is approached
from several angles.
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Tolerant patients
We aim to analyze an independent set of tolerant renal
transplant recipients in an observational longitudinal
study. Working with samples from newly recruited oper-
ationally tolerant patients identified by the collaborating
centers around Europe, we are performing the assays
described in the IoT fingerprint5 to assess their probability
of being tolerant. This will provide further important
information on the validation of the previously identified
biomarkers. In addition, because of the acquisition of
new equipment and expertise within the research team, a
selection of new flow cytometry parameters and a combina-
tion of new genes have also been included into the analyses.
Finally, we are performing further screening of the biomar-
kers to be conducted over a period of 3 years in previously
identified tolerant patients, testing the important aspect of
the stability of the fingerprint. To keep assessing the
specificity of the signature, we will also recruit healthy
volunteers, patients under different degrees of IS because of a
transplant, and patients taking immunsosuppression treat-
ment because of other immunological causes apart from
transplantation, such as autoimmune diseases.
Long-term stable kidney function
This part of the study will compare the biomarker signature
among patients with stable graft function under conventional
IS with patients undergoing chronic rejection. We expect the
signature to be present in a small percentage (5–10%, based
on the IoT analyses) of patients with stable kidney function.
Identifying patients under IS, who may be labeled ‘tolerant’, is
a crucial step toward translating these biomarkers into the
clinic.
IS withdrawal
We will assess the frequency of patients showing the tolerance
signature in an observational, prospective study of kidney
transplant patients who are undergoing steroid withdrawal
within 1 year post-transplantation. This protocol will also
identify whether patients under IS withdrawal acquire the
signature over time, allowing us to test the usefulness of the
fingerprint as a biomarker for successful drug weaning.
Basic research
In parallel to these translational projects, we will investigate
the role of B cells in tolerance in more detail as a follow-up of
the B-cell function enrichment found in the genetic
signature. Indeed, since the IoT and ITN studies, the role
of B cell in transplantation tolerance has been further
confirmed by others.12 The goal is to examine whether any
unique phenotypic or functional characteristics can be
identified within the subsets of these expanded cells during
operational tolerance. An understanding of the mechanistic
basis of the tolerant state would not only allow us to better
identify it, but also permit the development of molecular or
cellular targets for tolerance induction therapy in renal
transplant patients.
OTHER MULTINATIONAL EFFORTS IN DETECTING
TRANSPLANT TOLERANCE
Detecting and/or inducing tolerance requires large multi-
center networks that facilitate patient recruitment and ensure
the necessary technical and scientific expertise. Several
institutions are running projects with similar aims (Table 1).
Immediately after the IoT study commenced, the RISET
consortium was formed with similar aims: the development
of reliable tests to predict tolerance, with a view to assess
patients enrolled in RISET pilot clinical studies. Further,
RISET aimed to stimulate debate regarding ethical aspects of
tolerance induction protocols and establish educational
programs in transplantation tolerance, not only for scientists
and clinicians but also for patients and their families.18 The
RISET consortium is currently compiling the final report to
summarize their activities. The first study to emerge in the
Framework 7th research program from the EU commission is
THE ONE study. This study led by Dr Geissler in Regensburg
is going to test a number of cellular therapies to induce
tolerance in kidney transplantation in several European
centers.
The ITN is presently funding several clinical trials in solid
organ transplantation, as a continuum of the biomarkers of
tolerance study. One of these studies, ARTIST (An Observa-
tional Study to Assess the Prevalence of a Tolerance Signature
in Renal Transplant Recipients),13 aims to examine a large
cohort of renal transplant recipients in order to prospectively
determine the frequency and stability of the tolerance
signature in patients maintained on IS treatment. The ITN
has also made a worldwide call to locate operationally
tolerant patients in an effort to create an additional Registry
of Tolerant Kidney Transplant Recipients. Finally, the
Gradual Withdrawal of Immunosuppression in Patients
Receiving a Liver Transplant (AWISH)17 study aims to
investigate whether liver transplant recipients can be weaned
from immunosuppressive drugs under medical supervision.
Another active group within the tolerance biomarker field,
based at Stanford University in the United States, is headed
by Professor Minnie Sarwal. Their work focuses on candidate
gene expression studies in both adult and pediatric liver and
kidney transplant patients.15 In collaboration with Professor
Jean Paul Soullilou’s team, the group described a transcrip-
tional profile, specific for operational tolerant patients in
2007.19 In Barcelona, the group headed by Dr Sanchez-Fueyo
is focused on the characterization of biomarkers predictive of
tolerance in the setting of liver transplantation. Their findings
to date have led to the description of the first protocol in
clinical transplantation, in which a tolerance signature has
been used to monitor disease and inform decisions on drug
withdrawal.20
METHODOLOGICAL CHALLENGES IN THE STUDY
OF BIOMARKERS OF TOLERANCE
The major methodological challenge associated with the
study of tolerance in kidney transplantation is the ‘hidden’
nature of the phenotype. The tolerance state is, as yet,
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unknown. The patients voluntarily or directed are weaned off
IS for a long period of time, and this is not accompanied by
rejection; therefore, we assume are tolerant. It is important to
point out that any molecular changes may have already
occurred because of the tolerance state; however, it may also
be partially due to the absence of immunosuppression. For
this reason, biomarker studies of tolerance to date have been
purely cross-sectional, where patients at all stages of the post-
transplant period are allocated to defined clinical groups. As
a consequence, it is unknown when the tolerant signature
arises and how it develops from the time of transplant. For
example, it is unknown whether the signature detected by
these studies is detectable if the tolerant patients are still
under IS. This raises the problem of the appropriate control
comparison group for tolerant patients. Enrolling healthy
volunteers can serve as a control for the absence of
immunosuppressive drugs, whereas stable patients or chronic
rejectors are the ideal clinical comparison groups. It is
expected that long-term immune monitoring studies will
shed light into this question, making use of a more
appropriate longitudinal design, and providing the most
valuable type of data for this purpose; that is, the molecular
differences between tolerant and stable/chronic rejection
patients before successful weaning. Unfortunately, long-
itudinal studies currently rely on the independent decision
of the patients to withdraw their medication, which is a rare
and unsafe event. The rarity of the event puts limits to the
statistical power of tolerance studies, whereas the high risk
limits experimental allocation of patients to a ‘tolerant’
condition, as it is not currently ethically appropriate to
encourage a patient to undergo weaning. Another interesting,
and probably more feasible, design is to detect and follow up
patients who are partially weaned off immunosupression for
clinical reasons. Comparing the molecular changes in
patients who succeed the process with no rejection episodes
and those who suffer rejection as a consequence would help
to further disentangle the tolerance signature from the drug’s
signature.
To confront the problem of statistical power, most studies
establish multicenter and often international collaborations,
which necessarily introduce noise due to stratification effects
in genetic variation, and differences across countries and
centers in clinical protocols. A clear definition of the
phenotypes, that is, Stable vs. Tolerant vs. Chronic Rejector,
and a careful choice of inclusion and exclusion criteria can
help minimize the noise in the data. Thus, although a
predictive model is better validated when replicated in
miscellaneous populations,21 the original development
should be carried out using a restrictive phenotype, for
example, ‘A tolerant patient is that who has ceased all
medication for at least 1 year, has not suffered any episodes of
acute rejection or displayed indications of deteriorating/
chronic kidney dysfunction, and whose kidney function has
changed o15% in the previous year’ is a better candidate
than ‘A tolerant patient who has ceased all medication and
has not suffered allograft failure’. Generalization to a broader
definition of tolerance can be tested subsequently through
external validation in an independent patient sample, and the
test can be updated when necessary for its application in
significantly different populations.22 In addition, the effects
of known confounders can be tested explicitly by adding
clinical information to the multivariate predictor, for
example, donor type, number of transplants, time since
transplant, age of donor and recipient, human leukocyte
antigen mismatch, and so on.
WHAT MAKES A GOOD BIOMARKER STUDY?
We will now consider the component parts of a well-designed
biomarker study. In a recent review, Naesens and Sarwal21
argued that ‘omics’ data are currently being used in clinical
studies for two different purposes: predictive biomarker
discovery, and elucidation of pathophysiological processes to
identify therapeutic targets. The ultimate goals of biomarker
studies are prediction and prognosis, and this needs to be
recognized at all stages of the study, from design planning to
data analysis and reporting (see glossary for a description of
methodological terms in this section).
Design
Prospective studies are preferred over cross-sectional studies,
and the selection of the time points of interest is a major
decision that cannot be taken lightly. It is our experience that
Table 1 | Examples of current international efforts towards conducting translational research and biomarker discovery in solid
organ transplantation
Transplant tolerance-related clinical study Organ Lead institution Country Ref.
Genetic analysis and monitoring of biomarkers of immunological
tolerance (GAMBIT)
Kidney King’s College London United Kingdom 10
An observational study to assess the prevalence of a tolerance
signature in renal transplant recipients (ARTIST)
Kidney ITN USA 13
ITN registry of tolerant kidney transplant recipients Kidney ITN USA 14
Prediction and mechanisms of transplantation tolerance Kidney Stanford University (Sarwal lab) USA 15
Effect of immunosuppression drug weaning on hepatitis C virus
(HCV)-induced liver damage after liver transplantation
Liver Hospital Clinic of Barcelona Spain 16
Gradual withdrawal of immunosuppression in patients receiving
a liver transplant (AWISH)
Liver ITN USA 17
Abbreviation: ITN, Immune Tolerance Network.
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involving a multidisciplinary team in the planning stages of
the study is vital to reach an optimal design and ensure a
smooth running of the study; for example, clinical team,
translational research team, laboratory technicians, data
manager, and statisticians. An ideal biomarker or set of
biomarkers should show significant differences between
tolerant and non-tolerant patients either in mean expression
at a specified time point after transplant, or in the slope of
expression estimated across a number of repeated measures.
Data analysis
Naesens and Sarwal21 propose an ‘integrative omics
approach’ for translational research. Although it is clear that
‘cross-platform’ multivariate predictors that incorporate
different types of ‘omics’ data are the future, this imposes a
serious statistical challenge. The issues associated with the
processing and analysis of high-dimensional microarray data
have been broadly discussed elsewhere.23,24 In the context of
biomarker studies, it is important to use a data-analysis
protocol that places classification accuracy as the top priority.
The feature selection method should ideally:
(1) use misclassification error or other measures of classifica-
tion accuracy as criteria for feature selection (genes,
molecules, and so on), rather than simply P-values, for
example, predictive analysis of microarrays, significant
analysis of microarrays, supervised principal components;
(2) consider the performance of the features in combination
rather than individually in the selection process, for
example, classification trees, principal components
analysis, regularized regression;
(3) be sensitive to correlations and/or interactions between
the features, for example, random forest or elastic net
(see Hastie et al.25 for an extensive review of data mining
methods).
Subsequently, different classification algorithms can be
used to build the final predictive model, and the most
appropriate will depend on the data, the proficiency of the
analysis team, and the complexity of interactions and
correlations present in the selected features. Recently, the
MicroArray Quality Control (MAQC) consortium24 demon-
strated that ‘good modeling practices were more important
than the choice of a particular algorithm’ (p 834). Four key
points are to be taken from this report: (1) maintain a
reasonable ratio of sample size to classifier complexity;
(2) use internal validation (cross-validation or bootstrap-
ping) throughout feature selection and development of the
classifier, not only at the end; (3) perform external validation
in a completely independent sample; and (4) all the steps and
decisions taken during the classifier-building procedure
should be carefully documented and justified. This last
point brings us to the importance of a full report of
the analysis process, as well as the use of appropriate
measures of performance, to facilitate replication by other
research teams.
Reporting
The value of a biomarker depends on its ability to
discriminate different groups of patients, and in this case
tolerant vs stable and/or chronic rejectors, but this should
not be the only outcome. In a recent publication, Steyerberg
et al.22 describe classic and novel ways to evaluate the
predictive value of a new marker. According to these authors,
it is essential to quantify the value added by the new marker
to currently available, easier to obtain (clinical) variables.
Furthermore, accuracy measures such as sensitivity and
specificity, or area under the receiving operating curve,
provide incomplete information regarding the performance
of the new test. Calibration measures are needed to compare
outcomes and predictions, especially in the external valida-
tion stage; measures related to reclassification provide
detailed information regarding the gain of adding a new
marker; more importantly, a good sensitivity is not
necessarily translated into clinical usefulness, and decision-
curve analysis can help to evaluate the value of a marker,
taking into consideration the drawbacks and benefits of false
positives and true positives, respectively.
Overall, reports of discovery of new biomarkers, or
validation of previous ones, need to focus around a
comprehensive description of accuracy of classification and
clinical usefulness added to existing clinical measures. A
detailed disclosure of the final predictive model, including
values of coefficients, is desired to allow for a complete
replication and validation by others. Copyrights should be
protected by patent applications, rather than by lack of
transparency in scientific reports.
THE FUTURE: TRANSLATION OF BIOMARKERS INTO THE
CLINIC
Advances in our understanding of human immunological
processes and developments in new therapeutic and diag-
nostic agents make the detection and/or induction of graft
tolerance a real possibility in the near future. Many
therapeutic agents with potential tolerogenic properties have
been described, and some of them are currently undergoing
clinical trials (reviewed in St Clair et al.26). However, the lack
of well-defined biomarkers of tolerance represents the most
significant barrier to the development of tolerance therapeu-
tics. Without these tools, studies will miss an appropriate
clinical endpoint to define the operational tolerance state.
Long-term prospective studies could address the generation
of tolerance but only in the context of IS withdrawal
protocols. The only chance for a weaning study to be
successful will be a carefully designed one, in which weaning
is considered in the presence of increased surveillance and
using validated biomarkers of both rejection and tolerance
(Figure 1). Notwithstanding, this will imply in the
case of kidney allografts a real risk of graft loss. The current
efforts in establishing validated and stable biomarkers of
tolerance in combination with validated and widely accepted
biomarkers of rejection will allow such study to be ethically
acceptable.
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The road to the discovery of biomarkers has been
enormously boosted by the advances of new tools for high-
throughput analysis, which enable us to interrogate the
genome, epigenome, transcriptome, and proteome. Together
with these advances, new methods for data analysis are also
being developed to embrace this new multidimensional data
in a holistic rather than reductionistic perspective. The
discovery process implies the establishment of correlations
between gold standard clinical parameters of disease and
changes in biomarkers. To do so, there is a real need for a
coordinated approach between international networks to
create common biobanks associated with comprehensive
clinical records. This is of particular importance in the
process of biomarker validation, where large-scale prospective
multicenter studies are required. New initiatives such as the
Biomedical Research Centers27 in the United Kingdom are of
outstanding importance in bringing together both clinical and
research expertise, which is an essential step to optimize the
resources and funding that translational projects require.
CONCLUDING REMARKS
We aspire that validation of the biomarkers of tolerance will
conclude in a clear and robust definition of the hidden
phenotype of immune tolerance. This definition will have
multiple benefits that will ultimately impact the management
of kidney transplant recipients. We foresee a new paradigm in
transplantation medicine, where patients will be stratified
based on pretransplant-established risk factors such as
human leukocyte antigen matching or cold ischemia times,
and post-transplant monitoring of non-invasive biomar-
kers.28 Together, the studies described here provide evidence
that it might be possible to develop biomarkers capable of
detecting operational tolerance in kidney transplantation. We
expect that, in the near future, together with clinical and
histological information, better characterized molecular and
cellular markers will help us predict the outcome in kidney
transplantation, guide personalized IS and weaning proto-
cols, and even develop new therapeutic targets.
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Figure 1 |Biomarker-led management of kidney transplants. Pretransplant assessment: risk is assigned according to anti-donor immune
responses, anti-donor antibodies, human leukocyte antigen (HLA) mismatches, and genetic risk. Biomarkers of rejection will assess whether
acute rejection will develop in the initial months post-transplantation, the time period depending on the depletion agent used.
To maximize organ function, the treatment could be modified before tissue injury occurs. Two time points use biomarkers of tolerance:
first, to establish the success of any peritransplant tolerance-inducing protocol. Later, to establish whether a tolerance state has been
reached, the main aim would be to wean those patients off with positive biomarkers of tolerance. Throughout weaning, biomarkers
of rejection could be used to stop the process before tissue injury is evident. Obviously, if a patient is negative for the biomarkers
of tolerance, then the standard protocol of immunosuppression should be maintained for life.
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GLOSSARY OF METHODOLOGICAL TERMS
Confounder: a variable (measured or not) other than the predictor variables (biomarkers) potentially associated with the outcome variable. Failing
to consider it can result in a biased estimate of the association between biomarker and outcome.
Feature selection: the process of selecting a subset of predictor variables (biomarkers) from a highly dimensional set (e.g. microarray) based on their
association with the outcome variable (e.g., clinical groups).
Classifier/predictive model: a statistical model or algorithm used to predict the outcome variable (or probability of outcome) from the observed
values in the predictor variable/s (biomarker/s).
Discrimination: the ability of a classifier to differentiate between individuals with and without the outcome. Measures of discriminative performance
are the concordance (c) statistic for quantitative outcomes, and the area under the receiver operating characteristic curve (AUC of ROC).
ROC curve: a plot of sensitivity (true positive rate) against 1-specificity (false positive rate) for consecutive cutoffs for the probability of an outcome
predicted by the classifier.
Internal validation: determining the reproducibility of the predictive model in the development (training) sample via:
Cross-validation: dividing the sample in random groups, leaving one group out to develop the classifier, and testing its performance in the
remaining group. This procedure is repeated until all groups serve as test sample, and the whole process repeated a number of times to obtain a
stable average estimate of performance.
Bootstrapping: drawing samples with replacement from the original sample a sufficient number of times to obtain a stable estimate of performance.
External validation: the process of testing the generalizability of the performance of a predictive (biomarker) model in an independent sample, from
a ‘plausibly related’ population.
Calibration: the agreement between observed outcomes and predictions. Calibration-in-the-large is the difference between average predicted
outcome and average outcome in an independent sample. The calibration slope is related to the strength of the predictors’ effects, and how those
replicate in an independent sample.
Clinical usefulness: evaluation of the performance of a predictive model taking into account the relative importance of false-positive and false-
negative decisions in a clinical decision context. Decision curve analysis is the application of the ROC curve method to choose an optimal cutoff that
considers a weighted error rate.
Note: see Hastie et al. 25 and Newell et al.6 for a more detailed description of these terms.
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